OncLive® On Air
OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
Mentioned books
Jan 13, 2022 • 15min
S6 Ep25: Basu on Getting Ahead of the Shadow Curve of COVID-19 in Oncology
Dr Basu discusses the “shadow curve” that could result from disruptions in cancer care during the COVID-19 pandemic and innovative strategies that Cancer Treatment Centers of America are taking to avoid this.
Jan 10, 2022 • 23min
S6 Ep24: Meyer Characterizes Current Approaches to Diagnosing, Managing, and Studying Cardiac Angiosarcoma
Dr Meyer discusses the rarity of cardiac angiosarcoma, optimizing detection strategies, surgical interventions, and chemotherapy for this patient population, and why immunotherapy has the potential to transform care for patients.
Jan 6, 2022 • 29min
S6 Ep23: Dietz Draws Attention to Gender Disparities in Breast Cancer
Dr Dietz discusses her experience as a woman in surgical oncology, the importance of bridging gender disparities, and her advice to women entering the health care industry.
Jan 3, 2022 • 14min
S6 Ep22: Gilbert on Gaining New Ground at Vanderbilt
Dr Gilbert discusses her new role as associate director for research, education, and professional development at Vanderbilt University Medical Center and shares some of her short- and long-term goals in this position.
Dec 30, 2021 • 10min
S6 Ep21: Bardia on Sacituzumab Govitecan’s Current and Potential Future Position in TNBC
Dr Bardia discusses the role of sacituzumab govitecan in the treatment of patients with metastatic triple-negative breast cancer, the influence of the National Comprehensive Cancer Network guidelines on treatment recommendations and sequencing in the second-line setting, and ongoing research with the agent in the neoadjuvant setting.
Dec 27, 2021 • 10min
S6 Ep21: Gasparetto Talks Management Strategies for Belantamab Mafodotin–Related Ocular Toxicity in Myeloma
Dr Gasparetto discusses the management of ocular toxicities associated with belantamab mafodotin, the nuances of dose modification, and the potential for retreatment following toxicity resolution.
Dec 23, 2021 • 12min
S6 Ep20: Phillips Reflects on Lessons Learned With BTK Inhibitors in MCL
Dr Phillips discusses the utility of ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma, the impact of long-term follow-up data with ibrutinib, and findings from the phase 3 SYMPATICO trial that could shake up the treatment paradigm.
Dec 20, 2021 • 19min
S6 Ep19: Schwartzberg on Bringing Seminal Observations on AR From Bench to Bedside in ER+ Breast Cancer
Dr. Schwartzberg discusses the rationale to evaluate enobosarm in AR-positive, ER-positive advanced breast cancer, phase 2 data with the agent, and expectations for the ongoing phase 3 ARTEST trial in this population.
Dec 16, 2021 • 9min
S6 Ep18: Hochster Underscores Headway Made in Gastric/GEJ Cancers
Dr. Hochster provides insight into the current gastric/GEJ landscape, spotlighting molecular testing approaches, the roles of chemoimmunotherapy combinations, ongoing research with biomarkers of response, and optimal treatment sequencing for patients with HER2-positive disease.
Dec 13, 2021 • 27min
S6 Ep17: Shah and Wang Share Insights Into Optimized CAR T-Cell Therapy in Hematologic Malignancies
Dr. Shah and Dr. Wang discuss the management of cytokine release syndrome and neurotoxicity, the referral process, and the need for academic and community collaboration for CAR T-cell therapy in hematologic malignancies.
